Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | HTR2C | P28335 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | DRD2 | P14416 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HTR7 | P34969 | 2/20 | 0.72 |
| ▸ | HTR6 | P50406 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | DRD4 | P21917 | 1/20 | 0.72 |
| ▸ | HTR1D | P28221 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464512 | 0.94 | HTR2A (0.64) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| SCHEMBL8018901 | 0.88 | HTR2A (0.78) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| SCHEMBL14271386 | 0.84 | HTR2A (0.52) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL29361038 | 0.84 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL4862503 | 0.84 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL34294 | 0.84 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL1532014 | 0.83 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL2030457 | 0.83 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL30028921 | 0.83 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| SCHEMBL3890962 | 0.82 | HTR2A (0.66) | HTR2ACYP3A4HPGDCYP1A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763523-B1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-20 | — | — | EP | claimed |
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9255080-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-09 | — | — | US | disclosed |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-8623884-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2012-03-15 | — | — | US | disclosed |
| US-8080557-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| US-4335127-A | POTENT SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
| EP-0013612-A2 | (Piperidinylalkyl)quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | HTR2A 836/4885CYP3A4 506/4885HPGD 201/4885 |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | PARP1, PARP2, PARP3 | HTR2A 836/4885CYP3A4 506/4885HPGD 201/4885 |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | HTR2A 836/4885CYP3A4 506/4885HPGD 201/4885 |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | HTR2A 836/4885CYP3A4 506/4885HPGD 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.